Pihkala J, Sariola H, Saarinen U M
Children's Hospital, University of Helsinki, Finland.
Pediatr Hematol Oncol. 1994 May-Jun;11(3):259-69. doi: 10.3109/08880019409141669.
In an autopsy series of children with cancer, histopathologic myocardial changes caused by anthracyclines (A) were evaluated. The series comprised three groups: group A, 9 patients given A whose myocardial function had been evaluated before death; group B, 10 patients given A, but no lifetime echocardiographic evaluation; group C, 8 patients treated with chemotherapy regimens not including A. Both the cumulative A dose (P < 0.01) and the age of the patient at death (P < 0.001) were correlated with the pathologic changes in the myocardium. In echocardiography of group A patients, left ventricular (LV) contractility was subnormal in 5 (56%) patients, and the afterload was elevated in 3 (33%); the morphologic changes correlated with the LV wall stress (= afterload) (P < 0.05) and with LV fractional shortening (P < 0.04). We conclude that clinical decisions about A therapy should be based on cumulative A dose and myocardial function tests. Myocardial biopsies should be restricted to selected cases.
在一组儿童癌症尸检病例中,对蒽环类药物(A)所致的组织病理学心肌改变进行了评估。该组病例分为三组:A组,9例接受A治疗且在死亡前已评估心肌功能的患者;B组,10例接受A治疗但未进行终生超声心动图评估的患者;C组,8例接受不包括A的化疗方案治疗的患者。蒽环类药物的累积剂量(P < 0.01)和患者死亡时的年龄(P < 0.001)均与心肌的病理改变相关。在A组患者的超声心动图检查中,5例(56%)患者左心室(LV)收缩功能异常,3例(33%)患者后负荷升高;形态学改变与左心室壁应力(=后负荷)(P < 0.05)和左心室缩短分数(P < 0.04)相关。我们得出结论,关于A治疗的临床决策应基于蒽环类药物的累积剂量和心肌功能测试。心肌活检应限于特定病例。